A photo of Mark Mitsnefes.

Director, Clinical and Translational Research Center

Pediatric Nephrologist, Division of Nephrology

Professor, UC Department of Pediatrics



Board Certified

Best Doctors logo

My Biography & Research


Mark Mitsnefes, MD, MS, is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.

Dr. Misnefes has received numerous awards, including the Procter Scholar Award (Cincinnati Children's Research Foundation), the Pediatrician Scientist Award (Children's Health Research Center, NIH), the Clinical Scientist Award (National Kidney Foundation), and has been ranked as one of the Best Doctors in America, 2007-2011.

Additional Languages


Clinical Interests

Chronic renal disease, dialysis, renal transplantation, hypertension

Research Interests

Cardiovascular complications of chronic renal disease, clinical trials in hypertension

Academic Affiliation

Professor, UC Department of Pediatrics


Nephrology and Hypertension, Kidney Transplant, Kidney Disease, End-Stage Renal Disease, Nephrology and Hypertension

My Locations

My Education

MD: Gorky Medical Institute, Gorky, Russia, 1985.

Residency: Miami Children's Hospital, Miami, FL, 1997.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2000.

MS: Epidemiology and Biostatistics, University of Cincinnati, Cincinnati, OH, 2001.

Certifications: Educational Commission for Foreign Medical Graduates (ECFMG), 1995; Pediatrics, 1996; Pediatric Nephrology, 2001, 2008.

My Publications

Association between BMI changes and mortality risk in children with end-stage renal disease. Roberts, MJ; Mitsnefes, MM; McCulloch, CE; Greenbaum, LA; Grimes, BA; Ku, E. Pediatric Nephrology. 2019; 34:1557-1563.

Association of Blood Pressure Level With Left Ventricular Mass in Adolescents SHIP AHOY. Urbina, EM; Mendizabal, B; Becker, RC; Daniels, SR; Falkner, BE; Hamdani, G; Hanevold, C; Hooper, SR; Ingelfinger, JR; Lanade, M; et al. Hypertension. 2019; 74:590-596.

Cardiovascular disease in young adults with incident ESRD. Ku, E; Mitsnefes, MM. Nature Reviews Nephrology. 2019; 15:390-391.

When to Initiate Dialysis in Children and Adolescents: Is Waiting Worthwhile?. Nehus, E; Mitsnefes, MM. American Journal of Kidney Diseases. 2019; 73:762-764.

Cardiovascular Risk Reduction in High-Risk Pediatric Patients A Scientific Statement From the American Heart Association. de Ferranti, SD; Steinberger, J; Ameduri, R; Baker, A; Gooding, H; Kelly, AS; Mietus-Snyder, M; Mitsnefes, MM; Peterson, AL; St-Pierre, J; et al. Circulation. 2019; 139:E603-E634.

Ambulatory blood pressure monitoring tolerability and blood pressure status in adolescents: the SHIP AHOY study. Hamdani, G; Flynn, JT; Daniels, S; Falkner, B; Hanevold, C; Ingelfinger, J; Lande, MB; Martin, LJ; Meyers, KE; Mitsnefes, M; et al. Blood Pressure Monitoring. 2019; 24:12-17.

Childhood Obesity and the Metabolic Syndrome. Nehus, E; Mitsnefes, M. Pediatric Clinics of North America. 2019; 66:31-43.

Plasma glucosylceramides and cardiovascular risk in incident hemodialysis patients. Mitsnefes, MM; Fitzpatrick, J; Sozio, SM; Jaar, BG; Estrella, MM; Monroy-Trujillo, JM; Zhang, W; Setchell, K; Parekh, RS. Journal of Clinical Lipidology. 2018; 12:1513-1522.e4.

Cardiometabolic Risk Factors, Metabolic Syndrome, and Chronic Kidney Disease Progression in Children. Lalan, S; Jiang, S; Ng, DK; Kupferman, F; Warady, BA; Furth, S; Mitsnefes, MM. The Journal of Pediatrics. 2018; 202:163-170.

Cardiovascular Disease in Children and Adolescents With Chronic Kidney Disease. Jr, WD J; Mitsnefes, M. Seminars in Nephrology. 2018; 38:559-569.